 |
Scientific Advisory Board
- Steven W. Dow, DVM, Ph.D., Co-Founder, Colorado State University
- Denny Liggitt, DVM, Ph.D., Co-Founder, University of Washington
- David B. Lewis, M.D., Stanford University
- Bali Pulendran, Ph.D., Emory University Vaccine Center
- Stanley Lemon, M.D., University of Texas Medical Branch
- Rich Whitley, M.D., University of Alabama School of Medicine
Steven W. Dow, DVM, Ph.D., Co-Founder
Colorado State University
Dr. Dow currently serves as Professor in the Departments of Clinical Sciences and Pathology in the College of Veterinary Medicine & Biological Sciences at Colorado State University. Dr. Dow formerly was an instructor and research scientist at the National Jewish Medical and Research Center in Denver, CO. His current research is in immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Prior to developing a cancer gene therapy program, his past research has studied animal models of chronic viral infection, as well as the role of CD8+ T cells in immunity to tuberculosis. Dr. Dow is experienced in the discovery and application of gene therapy to oncologic and immune-mediated diseases and holds patents related to cell regulation with gene therapy. Dr. Dow earned his B.A. from the University of Virginia, his DVM in veterinary medicine from the University of Georgia and his Ph.D. from Colorado State University.
^ back to top
Denny Liggitt, DVM, Ph.D., Co-Founder
University of Washington
Dr. Liggitt's current position is Professor and Chair in the Department of Comparative Medicine in the School of Medicine at the University of Washington in Seattle. Dr. Liggitt has been a founder of two biotech companies-Megabios Corp. (now Urigen Pharmaceuticals), a nonviral gene therapy company and DiagXotics, a diagnostic company where he is still affiliated. He is a consultant to several biotechnology companies in the US. Earlier, Dr. Liggitt headed the pathology department at Genentech, Inc., where he developed, designed and managed a multifaceted histology and pathology facility. Prior to Genentech, Dr. Liggitt was a tenured Associate Professor of Veterinary Pathology at Washington State University. Dr. Liggitt earned his B.S. degree in veterinary science, DVM in veterinary medicine, and later his Ph.D. from Colorado State University.
^ back to top
David B. Lewis, M.D.
Stanford University
Dr. Lewis has 20 years of experience in cellular and molecular immunology. From 1985-1997, he was in the pediatrics and immunology departments at the University of Washington. Dr. Lewis joined Stanford University in 1997 as Associate Professor of Pediatrics, before becoming Professor of Pediatrics in 2005. He recently was also named Chief of Division of Immunology and Transplantation Biology. Dr. Lewis is trained as a clinical immunologist and pediatric infectious disease physician with extensive experience with both human and murine immunology systems. His research at Stanford University includes developmental defects in the neonatal immune system, the identification and characterization of newly emigrated T cells from the thymus (recent thymic emigrants or RTEs), and novel adjuvants for respiratory viruses. Dr. Lewis earned his B.S. degree in biology from Yale University summa cum laude, and his M.D. at the University of California, San Francisco.
^ back to top
Bali Pulendran, Ph.D.
Emory University Vaccine Center
Dr. Pulendran is a Professor in the Department of Pathology and Laboratory Medicine at the Emory University School of Medicine, having previously served as Associate Professor from 2002 to 2004. Prior to that, he was Director of the Rheumatoid & Respiratory Disease Groups at Aventis Pharmaceuticals from 2001 to 2002. Dr. Pulendran served as Assistant Professor, and later Associate Professor at Baylor Institute for Immunology Research from 1998 to 2001. Dr. Pulendran earned his B.A with honors from Queens' College, University of Cambridge, his Ph.D. in immunology from The Walter & Eliza Hall Institute of the University of Melbourne, Victoria, Australia, and did his post-doctoral training at Immunex Corporation.
^ back to top
Stanley Lemon, M.D.
University of Texas Medical Branch
Dr. Lemon is the John Sealy Distinguished University Chair and Director of the Institute for Human Infections and Immunity at the University of Texas Medical Branch (UTMB) at Galveston. He joined UTMB in 1997, serving first as Chair of the Department of Microbiology & Immunology, then as Dean of the School of Medicine from 1999 to 2004. From 1977 to 1983, Dr. Lemon served with the US Army Medical Research and Development Command, followed by a 14-year period on the faculty of the University of North Carolina School of Medicine. Dr. Lemon previously served as Chair of the Forum on Microbial Threats of the US Institute of Medicine, and recently co-chaired the National Research Council-Institute of Medicine study "Globalization, Biosecurity, and the Future of the Life Sciences." Dr. Lemon earned his undergraduate A.B. degree in biochemical sciences from Princeton University summa cum laude, and his M.D. with honor from the University of Rochester. He completed postgraduate training in internal medicine and infectious diseases at the University of North Carolina at Chapel Hill, and is board certified in both.
^ back to top
Rich Whitley, M.D.
University of Alabama School of Medicine
Dr. Whitley is Professor of Pediatrics, Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham. He also serves as the Loeb Scholar in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the institution. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a past President of the International Society of Antiviral Research, chairs the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is Vice President of the Board of the Infectious Disease Society of America. Dr. Whitley earned his B.A. degree in chemistry from Duke University and his M.D. from the George Washington University. He subsequently completed an internship in pediatrics and a fellowship in infectious diseases/virology at the University of Alabama at Birmingham.
^ back to top
Disclaimer: Participation by members of the SAB does not constitute or imply endorsement by any one of the institutions of which an SAB member is affiliated.
^ back to top
|
|
